Results 191 to 200 of about 64,020 (335)

Gastric Inhibitory Polypeptide Receptor [PDF]

, 2020
openaire   +1 more source

Effects of Synthetic Human Gastric Inhibitory Polypeptide on Splanchnic Circulation in Dogs

, 1988
Masafumi Kogire, Kazutomo Inoue, Shoichiro Sumi, Ryuichiro Doi, Kyoichi Takaori, Mitsutoshi Yun, Nobutaka Fujii, Haruaki Yajima, Takayoshi Tobe   +8 more
openalex   +1 more source

Lowering of fasting and food stimulated serum immunoreactive gastric inhibitory polypeptide (GIP) by glucagon. [PDF]

, 1977
R. Ebert, R. Arnold, W. Creutzfeldt
openalex   +1 more source

Gastric Inhibitory Polypeptide Receptor (GIPR) Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells. [PDF]

Cancers (Basel)
Haase A, Alefeld E, Yalinci F, Meenen DV, Busch MA, Dünker N.   +5 more
europepmc   +1 more source

Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
Central illustration: Pathophysiological mechanisms linking diabetes mellitus and cardiovascular disease. Chronic hyperglycaemia, insulin resistance, and low‐grade inflammation contribute to endothelial dysfunction, myocardial fibrosis, and cardiomyocyte apoptosis.
Lilian Anagnostopoulou, Nikolaos Ktenopoulos, Anastasios Apostolos, Christos Fragoulis, Panayotis Vlachakis, Paschalis Karakasis, Marios Sagris, Nikias Milaras, Maria Drakopoulou, Andreas Synetos, Ioannis Kyriazis, Ioannis Ioannidis, Costas Tsioufis, Konstantinos Toutouzas   +13 more
wiley   +1 more source

Central blood volume in cirrhosis [PDF]

, 1993
Bendtsen, Flemming, Gerbes, Alexander L., Henriksen, Jens H.   +2 more
core   +1 more source

Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real‐World Evidence

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
Tirzepatide as adjunct to insulin in adults with type 1 diabetes and overweight or obesity shows the most consistent signal for body weight reduction, with possible improvements in HbA1c and insulin requirements. However, current evidence remains early, low‐certainty, and insufficient to establish long‐term efficacy or safety.
Giuseppina Alessia Acucella, Danilo Caponio   +1 more
wiley   +1 more source

Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption [PDF]

, 1983
R. Ebert, H Unger, W. Creutzfeldt
openalex   +1 more source

Natural Products as the Modulators of Gut Microbiota: A Pool for the Development of New Treatment Against Obesity?

Food Frontiers, Volume 7, Issue 3, May 2026.
Natural compounds regulate gut microbiota by improving microbial balance and increasing probiotics, which boost short‐chain fatty acid production to alleviate insulin resistance and inflammation. Additionally, they stimulate appetite‐suppressing hormones through bile acid signaling, while inhibiting pathogenic bacteria to repair intestinal barrier ...
Hongchao Yuan, Yau‐Yuen Chan, Guang Chen, Lin Xu, Cheng Zhang, Guoyi Tang, Yibin Feng, Ning Wang   +7 more
wiley   +1 more source

Assessment of the Drug–Drug Interaction Potential of Lotiglipron (PF‐07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Two Phase 1 open‐label studies were conducted in otherwise healthy participants, with BMI classified as overweight/obesity, to assess the potential of lotiglipron (a glucagon‐like peptide‐1 receptor agonist) as precipitant for pharmacokinetic (PK) drug–drug interactions (DDIs) when co‐administered with substrates of cytochrome P450 (CYP) 3A ...
Carol Cronenberger, Neeta B. Amin, Vu H. Le, Santos Carvajal‐Gonzalez, Amy L. Ashworth, Ellen C. Yi, Tilman Schuster, Yizhong Zhang, Robert C. Frederich, Gary S. Friedman, Ellen Q. Wang, Nikolaos Tsamandouras   +11 more
wiley   +1 more source